Founded in 1994, Pappas Ventures invests exclusively in the life sciences sector – biotechnology, biopharmaceuticals, drug delivery, medical devices and related ventures. Most recently, in April 2011, the firm’s portfolio company Plexxikon, Inc. was sold to Daiichi Sankyo for cash and contingent payments of up to $935 million. Pappas Ventures has more than $300 million in capital under management, and has guided the launch and/or development of more than 50 life sciences companies, including Cerexa (acquired by Forest Laboratories), Peninsula Pharmaceuticals (acquired by Johnson & Johnson), TargeGen (acquired by Sanofi-aventis), Syntonix (acquired by Biogen IDEC), NuVasive (IPO), and Anthera Pharmaceuticals (IPO). For more information about Pappas Ventures, please visit www.pappasventures.com.

BDC is Canada’s business development bank. From 100 business centres across the country, BDC promotes entrepreneurship by providing highly tailored financing, venture capital and consulting services to entrepreneurs. www.bdc.ca.

GO Capital LP is a $50 million venture capital fund that invests in Quebec seed-stage technology firms in the fields of cleantech, information technologies and life sciences. GO Capital is managed by its General Partner, the Business Development Bank of Canada.

The Fonds de solidarité FTQ helps drive our economy. With net assets of $7.7 billion as of November 30, 2010, the Fund is a development capital investment fund that channels the savings of Quebecers into investments in all sectors of the economy to help further Quebec's economic growth. The Fund is a partner, either directly or through its network members, in 2,052 companies. With its 577,511 owner-shareholders, it has helped, on its own or with other financial partners, to create, maintain and protect 150,133 jobs. For more information, visit www.fondsftq.com.

iNovia Capital manages seed and early stage venture capital funds, with a focus on helping entrepreneurs and innovators build successful companies in the sectors of information technology, life sciences and cleantech. iNovia Capital's value-added approach to early stage investing provides portfolio companies with capital, unique access to intellectual property from its partner academic institutions, and an extensive network of industry partners, advisors and sector-specific co-investors. For more information see www.inoviacapital.com.

Fonds Bio-Innovation is a limited partnership whose general partner is Gestion Bio-Innovation Inc., a CQVB subsidiary. Its backers are the FTQ Solidarity Fund and the CQVB. Fonds Bio-Innovation l.p. offers financing for biotechnology enterprise starts in Québec, business structuring, proof of concept, prototype development, intellectual property protection, identification of competitive advantage, market niches, and commercialization strategy. More information about Fonds Bio-Innovation is available at www.fondsbio-innovation.com.